Comments

ResMed Analyst Ratings

RMDNYSE
Logo brought to you by Benzinga Data
Trade with Public
Trade with Public
$259.51
4.841.90%
At close: Jan 13, 4:00 PM EST
$259.11
4.441.74%
Pre-Market: 4:08 AM EST
Q2 2026 Earnings in 14 days from now on Thu Jan 29th, after the market close
OverviewNewsEarningsOptionsDividends

Analyst Ratings

Insider TradesShort InterestGovernment TradesStock Report
Consensus Rating1
Overweight
Highest Price Target1
$330.00
Lowest Price Target1
$180.00
Consensus Price Target1
$275.07

ResMed Analyst Ratings and Price Targets | NYSE:RMD | Benzinga

ResMed Inc has a consensus price target of $275.07 based on the ratings of 18 analysts. The high is $330 issued by Citigroup on September 18, 2025. The low is $180 issued by Wolfe Research on September 18, 2024. The 3 most-recent analyst ratings were released by Stifel, Baird, and Baird on December 18, 2025, December 16, 2025, and November 3, 2025, respectively. With an average price target of $278.33 between Stifel, Baird, and Baird, there's an implied 7.42% upside for ResMed Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

1
Sep 25
4
1
Oct 25
1
Nov 25
1
Dec 25
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stifel
Baird
RBC Capital
Keybanc
Mizuho

1calculated from analyst ratings

Analyst Ratings for ResMed

Buy NowGet Alert
12/18/2025Buy Now0.34%Stifel$270 → $260MaintainsHoldGet Alert
12/16/2025Buy Now6.13%Baird$300 → $275DowngradeOutperform → NeutralGet Alert
11/03/2025Buy Now15.78%Baird$320 → $300MaintainsOutperformGet Alert
10/31/2025Buy Now16.94%RBC Capital$300 → $303MaintainsOutperformGet Alert
10/31/2025Buy Now15.4%Keybanc$298 → $299MaintainsOverweightGet Alert
10/31/2025Buy Now15.78%Mizuho$310 → $300MaintainsOutperformGet Alert
10/21/2025Buy Now17.32%Morgan Stanley$298 → $304MaintainsOverweightGet Alert
10/13/2025Buy Now8.06%Wells Fargo → $280Initiates → Equal-WeightGet Alert
09/18/2025Buy Now27.36%Citigroup → $330Initiates → BuyGet Alert
08/01/2025Buy Now11.92%Mizuho$270 → $290MaintainsOutperformGet Alert
08/01/2025Buy Now4.2%Stifel$240 → $270MaintainsHoldGet Alert
08/01/2025Buy Now15.78%RBC Capital$294 → $300MaintainsOutperformGet Alert
08/01/2025Buy Now25.43%UBS$285 → $325MaintainsBuyGet Alert
08/01/2025Buy Now15.01%Keybanc$274 → $298MaintainsOverweightGet Alert
08/01/2025Buy Now4.2%Piper Sandler$248 → $270MaintainsNeutralGet Alert
07/16/2025Buy Now13.47%RBC Capital$255 → $294UpgradeSector Perform → OutperformGet Alert
07/16/2025Buy Now4.2%Mizuho$250 → $270MaintainsOutperformGet Alert
04/24/2025Buy Now-1.59%RBC Capital$247 → $255MaintainsSector PerformGet Alert
04/24/2025Buy Now9.99%UBS$290 → $285MaintainsBuyGet Alert
04/24/2025Buy Now11.92%JP Morgan$286 → $290MaintainsOverweightGet Alert
04/24/2025Buy Now-4.29%Piper Sandler$260 → $248MaintainsNeutralGet Alert
04/24/2025Buy Now5.75%Keybanc$269 → $274MaintainsOverweightGet Alert
04/21/2025Buy Now3.82%Keybanc$280 → $269MaintainsOverweightGet Alert
03/05/2025Buy Now—Citigroup—UpgradeNeutral → BuyGet Alert
03/05/2025Buy Now-7.38%Stifel$250 → $240MaintainsHoldGet Alert
01/31/2025Buy Now10.38%JP Morgan$270 → $286MaintainsOverweightGet Alert
01/31/2025Buy Now8.06%Keybanc$266 → $280MaintainsOverweightGet Alert
01/31/2025Buy Now0.34%Piper Sandler$252 → $260MaintainsNeutralGet Alert
01/31/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
01/10/2025Buy Now-2.74%Piper Sandler → $252Initiates → NeutralGet Alert
12/13/2024Buy Now-3.52%Stifel → $250Initiates → HoldGet Alert
10/25/2024Buy Now-10.46%RBC Capital$224 → $232MaintainsSector PerformGet Alert
10/25/2024Buy Now2.66%Keybanc$251 → $266MaintainsOverweightGet Alert
10/25/2024Buy Now9.22%Baird$280 → $283MaintainsOutperformGet Alert
10/25/2024Buy Now—Needham—Reiterates → HoldGet Alert
10/01/2024Buy Now-13.55%RBC Capital$206 → $224MaintainsSector PerformGet Alert
10/01/2024Buy Now—Needham—Reiterates → HoldGet Alert
09/26/2024Buy Now4.2%B of A Securities$240 → $270MaintainsBuyGet Alert
09/24/2024Buy Now8.06%Baird → $280Initiates → OutperformGet Alert
09/18/2024Buy Now—Needham—Reiterates → HoldGet Alert
09/18/2024Buy Now-30.53%Wolfe Research → $180DowngradePeer Perform → UnderperformGet Alert
09/04/2024Buy Now-8.92%Needham → $236DowngradeBuy → HoldGet Alert
08/02/2024Buy Now-20.5%RBC Capital$204 → $206MaintainsSector PerformGet Alert
08/02/2024Buy Now-3.13%Keybanc$238 → $251MaintainsOverweightGet Alert
08/02/2024Buy Now-8.92%Needham$236 → $236ReiteratesBuy → BuyGet Alert
07/23/2024Buy Now-21.27%RBC Capital$200 → $204MaintainsSector PerformGet Alert
06/25/2024Buy Now—Oppenheimer—DowngradeOutperform → PerformGet Alert
06/24/2024Buy Now—Citigroup—DowngradeBuy → NeutralGet Alert
06/24/2024Buy Now-8.92%Needham$236 → $236ReiteratesBuy → BuyGet Alert
04/26/2024Buy Now-22.81%Oppenheimer$205 → $200MaintainsOutperformGet Alert
04/26/2024Buy Now-22.81%RBC Capital$187 → $200MaintainsSector PerformGet Alert
04/26/2024Buy Now-8.15%Keybanc$227 → $238MaintainsOverweightGet Alert
04/26/2024Buy Now-8.92%Needham$224 → $236MaintainsBuyGet Alert
04/01/2024Buy Now-13.55%Needham$215 → $224MaintainsBuyGet Alert
03/27/2024Buy Now-17.02%Mizuho$215 → $215MaintainsBuyGet Alert
02/06/2024Buy Now-12.39%Keybanc → $227Initiates → OverweightGet Alert
01/30/2024Buy Now-20.88%Oppenheimer$185 → $205MaintainsOutperformGet Alert
01/30/2024Buy Now-17.02%Mizuho$195 → $215MaintainsBuyGet Alert
01/26/2024Buy Now-24.74%Mizuho$180 → $195MaintainsBuyGet Alert
01/25/2024Buy Now-29.76%RBC Capital$181 → $182MaintainsSector PerformGet Alert
01/25/2024Buy Now-30.53%UBS$175 → $180MaintainsNeutralGet Alert
01/25/2024Buy Now-17.02%Needham$180 → $215MaintainsBuyGet Alert
01/09/2024Buy Now-24.74%JP Morgan$160 → $195MaintainsOverweightGet Alert
10/31/2023Buy Now-38.25%Mizuho$180 → $160MaintainsBuyGet Alert
10/27/2023Buy Now-34.78%Morgan Stanley → $169UpgradeEqual-Weight → OverweightGet Alert
10/16/2023Buy Now-32.46%Oppenheimer$275 → $175MaintainsOutperformGet Alert
10/12/2023Buy Now-22.04%RBC Capital$273 → $202DowngradeOutperform → Sector PerformGet Alert
09/29/2023Buy Now—Wolfe Research—DowngradeOutperform → Peer PerformGet Alert
09/18/2023Buy Now-11.23%B of A Securities$250 → $230MaintainsBuyGet Alert
09/13/2023Buy Now-30.53%Mizuho$255 → $180MaintainsBuyGet Alert
09/06/2023Buy Now-30.53%Needham → $180UpgradeHold → BuyGet Alert
09/05/2023Buy Now-34.39%UBS$265 → $170DowngradeBuy → NeutralGet Alert
08/14/2023Buy Now5.36%RBC Capital$284 → $273MaintainsOutperformGet Alert
08/04/2023Buy Now9.61%RBC Capital → $284ReiteratesOutperform → OutperformGet Alert
08/04/2023Buy Now-3.52%B of A Securities$260 → $250MaintainsBuyGet Alert
08/04/2023Buy Now0.34%Keybanc$280 → $260MaintainsOverweightGet Alert
08/01/2023Buy Now9.61%RBC Capital$262 → $284UpgradeSector Perform → OutperformGet Alert
05/22/2023Buy Now11.92%UBS → $290Initiates → BuyGet Alert
04/14/2023Buy Now-1.59%Mizuho → $255Initiates → BuyGet Alert
04/13/2023Buy Now-1.59%Mizuho → $255Initiates → BuyGet Alert
01/27/2023Buy Now0.34%JP Morgan$245 → $260MaintainsOverweightGet Alert
01/17/2023Buy Now-5.45%JP Morgan → $245UpgradeNeutral → OverweightGet Alert

FAQ

Q

What is the target price for ResMed (RMD) stock?

A

The latest price target for ResMed (NYSE:RMD) was reported by Stifel on December 18, 2025. The analyst firm set a price target for $260.00 expecting RMD to rise to within 12 months (a possible 0.34% upside). 29 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ResMed (RMD)?

A

The latest analyst rating for ResMed (NYSE:RMD) was provided by Stifel, and ResMed maintained their hold rating.

Q

When was the last upgrade for ResMed (RMD)?

A

The last upgrade for ResMed Inc happened on July 16, 2025 when RBC Capital raised their price target to $294. RBC Capital previously had a sector perform for ResMed Inc.

Q

When was the last downgrade for ResMed (RMD)?

A

The last downgrade for ResMed Inc happened on December 16, 2025 when Baird changed their price target from $300 to $275 for ResMed Inc.

Q

When is the next analyst rating going to be posted or updated for ResMed (RMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on December 18, 2025 so you should expect the next rating to be made available sometime around December 18, 2026.

Q

Is the Analyst Rating ResMed (RMD) correct?

A

While ratings are subjective and will change, the latest ResMed (RMD) rating was a maintained with a price target of $270.00 to $260.00. The current price ResMed (RMD) is trading at is $259.11, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch

Steris PLC
NYSE:STE
$264.25
%
Masimo Corp
NASDAQ:MASI
$138.41
%
Envista Holdings Corp
NYSE:NVST
$24.24
0.17%
Koninklijke Philips NV
NYSE:PHG
$30.07
-0.10%
Smith & Nephew PLC
NYSE:SNN
$33.07
0.45%
Abbott Laboratories
NYSE:ABT
$124.90
0.42%
Becton Dickinson & Co
NYSE:BDX
$207.42
%
Insulet Corp
NASDAQ:PODD
$282.89
%
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved